Entrada Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 159
- Market Cap
- $621.2M
- Website
- http://www.entradatx.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: ENTR-601-44 - matching placebo
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Entrada Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07037862
- Locations
- 🇧🇪
University Hospital Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇧🇪Centre Hospitalier Régional de la Citadelle, Liège, Belgium
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: ENTR-601-45 - matching placebo
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Entrada Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07038824
- Locations
- 🇧🇪
University Hospital Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇮🇹IRCCS Ospedale San Raffaele, Milan, Italy
Natural History Study of MNGIE
- Conditions
- Mitochondrial Neurogastrointestinal Encephalomyopathy
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Entrada Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04245917
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸Baylor St Luke's Medical Center and Texas Children's Hospital at Baylor College of Medicine, Houston, Texas, United States
News
Taiho's Pizuglanstat Fails to Meet Primary Endpoint in Phase III Duchenne Muscular Dystrophy Trial
Taiho Pharmaceutical's pizuglanstat (TAS-205) failed to demonstrate significant improvement in time to rise from floor compared to placebo in the Phase III REACH-DMD study.
Dyne's DYNE-251 Shows "Unprecedented" Functional Improvements in Duchenne Muscular Dystrophy Trial
• Phase I/II Deliver trial demonstrates sustained functional improvements in DMD patients treated with DYNE-251, showing mean absolute dystrophin expression of 8.72% above baseline at six months with the 20mg/kg dose. • The therapy, designed for patients amenable to exon 51 skipping, showed improvements across multiple functional endpoints including mobility assessments, positioning Dyne for potential accelerated FDA approval submission in early 2026. • If approved, DYNE-251 could generate significant market impact, with GlobalData projecting revenue growth from $5 million in 2025 to $129 million by 2030 in the competitive DMD treatment landscape.
Entrada Therapeutics Advances DMD Treatment: UK MHRA Approves Phase I/II Trial for Novel Exon-Skipping Therapy
Entrada Therapeutics has received MHRA authorization to commence ELEVATE-44-201, a Phase I/II trial evaluating ENTR-601-44 for Duchenne muscular dystrophy patients with exon 44 skipping mutations.